Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024 01:00 ET
|
Addex Therapeutics
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical...
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024 11:12 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
April 17, 2024 02:00 ET
|
F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
April 17, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
April 17, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now...
Feintool wins important contract in Europe’s hydrogen industry
April 17, 2024 00:30 ET
|
Feintool International Holding AG
The company is tasked with the production of high-precision metal components for fuel cells and electrolyzers. This successfully marks Feintool’s entry into the European market, following the...
Feintool gewinnt in Europa wichtigen Auftrag aus der Wasserstoffwirtschaft
April 17, 2024 00:30 ET
|
Feintool International Holding AG
Feintool wurde mit der Herstellung präziser metallischer Einzelkomponenten für Brennstoffzellen und Elektrolyseure beauftragt. Damit wird nach der Nominierung in China durch einen chinesischen...
Generalversammlung der Ascom beschliesst erhöhte Dividendenausschüttung von CHF 0,30
April 16, 2024 11:45 ET
|
Ascom Holding AG
Ad hoc Mitteilung gemäss Art. 53 KRBaar, Schweiz, 16. April 2024 Die Aktionäre der Ascom Holding AG haben an der ordentlichen Generalversammlung vom 16. April 2024 in Zug allen Anträgen...
Ascom Annual General Meeting approves increased dividend payout of CHF 0.30
April 16, 2024 11:45 ET
|
Ascom Holding AG
Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, April 16, 2024 At the Annual General Meeting held in Zug on April 16, 2024, the shareholders of Ascom Holding AG approved...